Prativa Sherchan1, Lei Huang2, Yuechun Wang1, Onat Akyol1, Jiping Tang1, John H Zhang3. 1. Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, U.S.A. 2. Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, U.S.A.; Department of Anesthesiology, Loma Linda University, CA 92354, U.S.A. 3. Department of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92354, U.S.A.; Department of Anesthesiology, Loma Linda University, CA 92354, U.S.A.; Department of Neurosurgery, Loma Linda University, CA 92354, U.S.A.. Electronic address: johnzhang3910@yahoo.com.
Abstract
BACKGROUND AND PURPOSE: Peripheral immune cell infiltration to the brain tissue at the perisurgical site can promote neuroinflammation after surgical brain injury (SBI). Slit2, an extracellular matrix protein, has been reported to reduce leukocyte migration. This study evaluated the effect of recombinant Slit2 and the role of its receptor roundabout1 (Robo1) and its downstream mediator Slit-Robo GTPase activating protein 1 (srGAP1)-Cdc42 on peripheral immune cell infiltration after SBI in a rat model. METHODS: One hundred and fifty-three adult male Sprague-Dawley rats (280-350 g) were used. Partial resection of right frontal lobe was performed to induce SBI. Slit2 siRNA was administered by intracerebroventricular injection 24h before SBI. Recombinant Slit2 was injected intraperitoneally 1h before SBI. Recombinant Robo1 used as a decoy receptor was co-administered with recombinant Slit2. srGAP1 siRNA was administered by intracerebroventricular injection 24h before SBI. Post-assessments included brain water content measurement, neurological tests, ELISA, Western blot, immunohistochemistry, and Cdc42 activity assay. RESULTS: Endogenous Slit2 was increased after SBI. Robo1 was expressed by peripheral immune cells. Endogenous Slit2 knockdown worsened brain edema after SBI. Recombinant Slit2 administration reduced brain edema, neurological deficits, and pro-inflammatory cytokines after SBI. Recombinant Slit2 reduced peripheral immune cell markers cluster of differentiation 45 (CD45) and myeloperoxidase (MPO), as well as Cdc42 activity in the perisurgical brain tissue which was reversed by recombinant Robo1 co-administration and srGAP1 siRNA. CONCLUSIONS: Recombinant Slit2 improved outcomes by reducing neuroinflammation after SBI, possibly by decreasing peripheral immune cell infiltration to the perisurgical site through Robo1-srGAP1 mediated inhibition of Cdc42 activity. These results suggest that Slit2 may be beneficial to reduce SBI-induced neuroinflammation.
BACKGROUND AND PURPOSE: Peripheral immune cell infiltration to the brain tissue at the perisurgical site can promote neuroinflammation after surgical brain injury (SBI). Slit2, an extracellular matrix protein, has been reported to reduce leukocyte migration. This study evaluated the effect of recombinant Slit2 and the role of its receptor roundabout1 (Robo1) and its downstream mediator Slit-Robo GTPase activating protein 1 (srGAP1)-Cdc42 on peripheral immune cell infiltration after SBI in a rat model. METHODS: One hundred and fifty-three adult male Sprague-Dawley rats (280-350 g) were used. Partial resection of right frontal lobe was performed to induce SBI. Slit2 siRNA was administered by intracerebroventricular injection 24h before SBI. Recombinant Slit2was injected intraperitoneally 1h before SBI. Recombinant Robo1 used as a decoy receptor was co-administered with recombinant Slit2. srGAP1 siRNA was administered by intracerebroventricular injection 24h before SBI. Post-assessments included brain water content measurement, neurological tests, ELISA, Western blot, immunohistochemistry, and Cdc42 activity assay. RESULTS: Endogenous Slit2was increased after SBI. Robo1 was expressed by peripheral immune cells. Endogenous Slit2 knockdown worsened brain edema after SBI. Recombinant Slit2 administration reduced brain edema, neurological deficits, and pro-inflammatory cytokines after SBI. Recombinant Slit2 reduced peripheral immune cell markers cluster of differentiation 45 (CD45) and myeloperoxidase (MPO), as well as Cdc42 activity in the perisurgical brain tissue which was reversed by recombinant Robo1 co-administration and srGAP1 siRNA. CONCLUSIONS: Recombinant Slit2 improved outcomes by reducing neuroinflammation after SBI, possibly by decreasing peripheral immune cell infiltration to the perisurgical site through Robo1-srGAP1 mediated inhibition of Cdc42 activity. These results suggest that Slit2 may be beneficial to reduce SBI-induced neuroinflammation.
Authors: Soumitra Tole; Ilya M Mukovozov; Yi-Wei Huang; Marco A O Magalhaes; Ming Yan; Min Rui Crow; Guang Ying Liu; Chun Xiang Sun; Yves Durocher; Michael Glogauer; Lisa A Robinson Journal: J Leukoc Biol Date: 2009-09-16 Impact factor: 4.962
Authors: Sachin Kumar; Juying Xu; Charles Perkins; Fukun Guo; Scott Snapper; Fred D Finkelman; Yi Zheng; Marie-Dominique Filippi Journal: Blood Date: 2012-08-29 Impact factor: 22.113
Authors: Nyall R London; Weiquan Zhu; Fernando A Bozza; Matthew C P Smith; Daniel M Greif; Lise K Sorensen; Luming Chen; Yuuki Kaminoh; Aubrey C Chan; Samuel F Passi; Craig W Day; Dale L Barnard; Guy A Zimmerman; Mark A Krasnow; Dean Y Li Journal: Sci Transl Med Date: 2010-03-17 Impact factor: 17.956
Authors: Paul R Krafft; Devin W McBride; Tim Lekic; William B Rolland; Charles E Mansell; Qingyi Ma; Jiping Tang; John H Zhang Journal: Behav Brain Res Date: 2014-02-08 Impact factor: 3.332
Authors: Cherine H Kim; Devin W McBride; Prativa Sherchan; Carl E Person; Eric C K Gren; Wayne Kelln; Tim Lekic; William K Hayes; Jiping Tang; John H Zhang Journal: Neurobiol Dis Date: 2017-03-09 Impact factor: 5.996
Authors: Brandon J Dixon; Di Chen; Yang Zhang; Jerry Flores; Jay Malaguit; Derek Nowrangi; John H Zhang; Jiping Tang Journal: ASN Neuro Date: 2016-09-28 Impact factor: 4.146